Logo

LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

Share this
LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

Shots:

  • The US FDA has granted FT Designation to LX1001 for the treatment of APOE4 associated AD. The designation evaluates to facilitate the development and expedite the review of drug
  • The company has initiated P-I trial to assess the safety and toxicity of LX1001 as a potential one-time treatment for early-stage AD patients with mild cognitive impairment who are APOE4 homozygous
  • The study will establish a maximum tolerable dose and is expected to complete dosing of 15 patients in 2021 while the initial P-I clinical data are expected in the H2’21

  Ref: Globe Newswire | Image: Yahoo Finance

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions